ストックスクリーナーアプリを入手
45.19
0.87%
0.39
Royalty Pharma Plc (RPRX) 最新ニュース
Envestnet Asset Management Inc. Purchases 339,839 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma: 2025 Financial Performance And Strategic Outlook - Seeking Alpha
(RPRX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Quarterly Recap: Is Royalty Pharma plc stock undervalued right now2025 Stock Rankings & Smart Allocation Stock Tips - baoquankhu1.vn
Royalty Pharma plc (NASDAQ:RPRX) Passed Our Checks, And It's About To Pay A US$0.235 Dividend - Yahoo Finance
Activity Recap: Does IONS stock benefit from AI growthJuly 2025 Update & High Conviction Trade Alerts - baoquankhu1.vn
Royalty Pharma to buy royalty interest in Amgen’s Imdelltra for up to $950M - MSN
Wall Street Zen Downgrades Royalty Pharma (NASDAQ:RPRX) to Buy - MarketBeat
Royalty Pharma targets 3%–8% royalty receipts growth in 2026 while advancing $4.7B in transactions - MSN
Royalty Pharma Earnings Call Balances Strength And Risk - TipRanks
Royalty Pharma (RPRX) Margin Reset To 32.6% Tests Bullish Profitability Narratives - Sahm
New South Capital Management Inc. Purchases 31,694 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Cookson Peirce & Co. Inc. Buys 338,623 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Will Royalty Pharma plc stock see insider buyingMarket Weekly Review & Growth Focused Stock Reports - mfd.ru
Risks Report: Is Royalty Pharma plc likely to announce a buybackWeekly Stock Recap & Intraday High Probability Setup Alerts - baoquankhu1.vn
Arrowhead Stock Has Skyrocketed 290% in One Year, and One Fund Trimmed Its Holdings by $4 Million - AOL.com
Royalty Pharma: Strong Execution And Visible Pipeline Support Our Buy View (NASDAQ:RPRX) - Seeking Alpha
S P Trends: Is Royalty Pharma plc likely to announce a buybackWeekly Stock Recap & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Royalty Pharma price target raised to $51 from $45 at Goldman Sachs - TipRanks
Royalty Pharma plc (NASDAQ:RPRX) Q4 2025 Earnings Call Transcript - Insider Monkey
BofA Securities reiterates Buy rating on Royalty Pharma stock with $54 target - Investing.com Nigeria
BofA Securities Reiterates Buy Rating on Royalty Pharma (RPRX) - StreetInsider
Royalty Pharma stock hits 52-week high at 44.94 USD By Investing.com - Investing.com Canada
Royalty Pharma's Disciplined Capital Allocation Approach and Appealing Market Growth Bolster Outlook - Morningstar
Royalty Pharma PLC (RPRX): A Strategic SWOT Insight - GuruFocus
Royalty Pharma Q4 2025 slides: double-digit growth amid synthetic royalty expansion - Investing.com Nigeria
UBS and Citi are bullish on Royalty Pharma plc (RPRX) – here’s why - MSN
Royalty Pharma earnings beat by $0.22, revenue fell short of estimates - Investing.com UK
Royalty Pharma plc (RPRX) Reports Q4 results - StreetInsider
Earnings Call Summary | Royalty Pharma(RPRX.US) Q4 2025 Earnings Conference - 富途牛牛
Royalty Pharma earnings beat by $0.22, revenue topped estimates - Investing.com Nigeria
Royalty Pharma (NASDAQ:RPRX) Sets New 1-Year HighHere's What Happened - MarketBeat
Royalty Pharma (NASDAQ:RPRX) Will Pay A Larger Dividend Than Last Year At $0.235 - simplywall.st
Royalty Pharma (RPRX) Strengthens Pipeline With New Oncology Royalty Purchase - MSN
Assessing Royalty Pharma (RPRX) Valuation After Recent Share Price Momentum - Yahoo Finance
Royalty Pharma stock hits 52-week high at 44.94 USD - Investing.com
Royalty Pharma (NASDAQ:RPRX) Announces Quarterly Earnings Results, Beats Estimates By $0.13 EPS - MarketBeat
RPRX: Double-digit growth, early capital deployment, and rising synthetic royalties drive strong outlook - TradingView
Earnings call transcript: Royalty Pharma beats Q4 2025 forecasts with strong EPS - Investing.com India
RPRX: Double-digit growth, early capital deployment, and strong 2026 outlook with cost savings - TradingView
Royalty Pharma Q4 Earnings Call Highlights - MarketBeat
Royalty Pharma (RPRX) Q4 2025 Earnings Transcript - The Globe and Mail
Here's What Key Metrics Tell Us About Royalty Pharma (RPRX) Q4 Earnings - Yahoo Finance
Royalty Pharma plc Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Royalty Pharma plc Provides Earnings Guidance for the Full Year 2026 - marketscreener.com
Royalty Pharma plc SEC 10-K Report - TradingView
Royalty Pharma (NASDAQ:RPRX) Reports Sales Below Analyst Estimates In Q4 CY2025 Earnings - Finviz
Royalty Pharma PLC-CL A (NASDAQ:RPRX) Shares Dip Despite Strong Portfolio Growth and 2026 Guidance Beat - ChartMill
Royalty Pharma Reports Q4 and Full Year 2025 Results - TradingView
Royalty Pharma's Q4 Net Income, Revenue Rise - marketscreener.com
Earnings Flash (RPRX) Royalty Pharma Posts Q4 Net Income $356M - marketscreener.com
Royalty Pharma reports Q4 portfolio receipts of $874M - TipRanks
Royalty Pharma Plc Bottom Line Advances In Q4 - Nasdaq
Royalty Pharma Q4 Earnings Report: What Investors Need to Know - Benzinga
Royalty Pharma PLC (RPRX) Q4 2025 Earnings Call Highlights: Strong Growth and Strategic Capital ... By GuruFocus - Investing.com Canada
Royalty Pharma earnings in focus after $4.7B deal spree By Investing.com - Investing.com Australia
Royalty Pharma earnings in focus after $4.7B deal spree - Investing.com
Royalty Pharma's Earnings: A Preview - Benzinga
Exploring Analyst Estimates for Royalty Pharma (RPRX) Q4 Earnings, Beyond Revenue and EPS - Yahoo Finance Australia
1.12%
0.35%
大文字化:
|
ボリューム (24 時間):